Gilead Sciences | GILD - Sales Revenues

Gilead Sciences reported $7.12B in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
AbbVie USD 14.3B 374M Dec/2023
Agios Pharmaceuticals USD 7.1M 296K Dec/2023
ALKERMES USD 377.48M 3.46M Dec/2023
Alnylam Pharmaceuticals USD 439.72M 310.81M Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
Biogen USD 2.29B 96.3M Mar/2024
BioMarin Pharmaceutical USD 649M 2.79M Mar/2024
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Eli Lilly USD 9.35B 145.2M Dec/2023
Gilead Sciences USD 7.12B 64M Dec/2023
GlaxoSmithKline GBP 8.05B 95M Dec/2023
Glaxosmithkline GBP 8.05B 95M Dec/2023
Incyte USD 1.01B 94.32M Dec/2023
J&J USD 21.38B 15M Mar/2024
Merck USD 15.8B 1.17B Mar/2024
Moderna USD 2.81B 980M Dec/2023
Neurocrine Biosciences USD 515.2M 16.4M Dec/2023
Novartis USD 11.83B 54M Mar/2024
Pfizer USD 14.25B 1.02B Dec/2023
PTC Therapeutics USD 210.12M 96.94M Mar/2024
Regeneron Pharmaceuticals USD 3.43B 71.6M Dec/2023
Sanofi EUR 10.92B 1.05B Dec/2023
Sarepta Therapeutics USD 396.78M 64.96M Dec/2023
United Therapeutics USD 614.7M 5.3M Dec/2023
Vertex Pharmaceuticals USD 2.52B 34.2M Dec/2023